Avita Medical (RCEL) Financials: History & Chart

Avita Medical Inc.(RCEL)

Medical - Devices · Valencia, CA

$12.94-0.31 (-2.33%)

Delayed quote: Oct 6, 2026, 1:10 PM EDT

About Avita Medical Inc.

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.

Valencia, CA

226 employees

avitamedical.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Cary G. Vance

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	75.63M	21.70M	19.25M	17.62M	17.06M	18.42M	18.51M	18.41M	19.55M
Cost of Goods Sold	13.95M	3.94M	3.52M	3.31M	3.19M	3.47M	2.83M	2.28M	3.19M
Gross Profit	61.68M	17.77M	15.73M	14.31M	13.88M	14.95M	15.68M	16.13M	16.36M
Gross Profit Margin	81.6%	81.9%	81.7%	81.2%	81.3%	81.2%	84.7%	87.6%	83.7%
Total Operating Expenses	96.90M	24.62M	24.53M	24.72M	23.03M	26.10M	27.51M	26.08M	30.16M
Research & Development	20.14M	5.08M	5.63M	5.69M	3.75M	5.12M	6.28M	4.85M	5.43M
Selling, General & Administrative	76.75M	19.54M	18.90M	19.03M	19.28M	20.98M	21.22M	21.23M	24.73M
Operating Income (EBIT)	-35.22M	-6.86M	-8.80M	-10.41M	-9.15M	-11.15M	-11.83M	-9.96M	-13.81M
Operating Margin	-46.6%	-31.6%	-45.7%	-59.1%	-53.6%	-60.5%	-63.9%	-54.1%	-70.6%
Income Before Tax (EBT)	-43.06M	-7.63M	-10.62M	-11.64M	-13.17M	-9.92M	-13.85M	-11.57M	-16.23M
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	5.41M	1.46M	1.42M	1.25M	1.27M	1.25M	1.23M	1.30M	1.36M
Other Income/Expense	-7.84M	-775K	-1.82M	-1.23M	-4.02M	1.23M	-2.02M	-1.61M	-2.43M
Net Income	-43.08M	-7.66M	-10.61M	-11.62M	-13.19M	-9.92M	-13.86M	-11.59M	-16.20M
Income Tax Expense	20K	33K	-11K	-17K	15K	4K	8K	19K	-28K
Net Profit Margin	-57.0%	-35.3%	-55.1%	-66.0%	-77.3%	-53.9%	-74.9%	-63.0%	-82.9%
EBITDA	-31.97M	-5.50M	-8.18M	-9.71M	-8.58M	-10.60M	-11.31M	-9.55M	-13.50M
EBITDA Margin	-42.3%	-25.4%	-42.5%	-55.1%	-50.3%	-57.5%	-61.1%	-51.9%	-69.0%
Depreciation & Amortization	3.25M	1.35M	627K	700K	574K	552K	521K	409K	310K
EPS Basic	-1.45	-0.25	-0.36	-0.38	-0.46	-0.38	-0.53	-0.44	-0.62
EPS Diluted	-1.45	-0.25	-0.36	-0.38	-0.46	-0.38	-0.53	-0.44	-0.62
Weighted Average Basic Shares	30.75M	30.75M	29.31M	30.38M	28.39M	26.37M	26.25M	26.15M	25.98M
Weighted Average Diluted Shares	30.75M	30.75M	29.31M	30.38M	28.39M	26.37M	26.25M	26.15M	25.98M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	06/30/2021	06/30/2020	06/30/2019
Revenue	71.61M	64.25M	50.14M	34.42M	33.02M	29.23M	14.26M	5.50M
Cost of Goods Sold	12.79M	9.09M	7.78M	6.04M	6.10M	5.95M	2.97M	1.28M
Gross Profit	58.82M	55.16M	42.36M	28.38M	26.92M	23.28M	11.29M	4.22M
Gross Profit Margin	82.1%	85.8%	84.5%	82.4%	81.5%	79.6%	79.2%	76.8%
Total Operating Expenses	101.35M	111.75M	85.02M	55.88M	52.04M	49.82M	53.97M	29.86M
Research & Development	20.84M	20.36M	20.82M	13.86M	15.67M	14.82M	9.16M	8.04M
Selling, General & Administrative	80.51M	91.39M	65.63M	45.24M	37.21M	37.06M	48.73M	27.77M
Operating Income (EBIT)	-42.53M	-56.59M	-42.66M	-27.50M	-25.12M	-26.54M	-42.68M	-25.64M
Operating Margin	-59.4%	-88.1%	-85.1%	-79.9%	-76.1%	-90.8%	-299.2%	-466.4%
Income Before Tax (EBT)	-48.58M	-61.79M	-35.31M	-26.63M	-25.10M	-26.55M	-42.03M	-25.33M
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	48K	N/A
Interest Expense	5.00M	5.36M	1.14M	16K	29K	22K	N/A	27K
Other Income/Expense	-6.04M	-5.20M	7.34M	876K	18K	-5K	653K	306K
Net Income	-48.59M	-61.84M	-35.38M	-26.66M	-25.14M	-26.58M	-42.03M	-25.21M
Income Tax Expense	11K	54K	66K	36K	42K	38K	4K	-122K
Net Profit Margin	-67.8%	-96.3%	-70.6%	-77.5%	-76.1%	-90.9%	-294.7%	-458.6%
EBITDA	-40.19M	-55.47M	-42.02M	-26.94M	-24.45M	-25.82M	-42.21M	-25.37M
EBITDA Margin	-56.1%	-86.3%	-83.8%	-78.3%	-74.0%	-88.3%	-296.0%	-461.4%
Depreciation & Amortization	2.35M	1.13M	632K	568K	673K	715K	465K	270K
EPS Basic	-1.74	-2.39	-1.40	-1.07	-1.03	-1.17	-2.07	-1.12
EPS Diluted	-1.74	-2.39	-1.40	-1.07	-1.03	-1.17	-2.07	-1.12
Weighted Average Basic Shares	27.86M	25.88M	25.33M	25.00M	24.36M	20.29M	20.29M	22.33M
Weighted Average Diluted Shares	27.86M	25.88M	25.33M	25.00M	24.36M	20.29M	20.29M	22.33M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.